Wall Street Analysts Adjust Price Targets for Toll Brothers, Bilibili, and Oruka Therapeutics

Wall Street analysts recently updated their outlooks on several stocks, including changes in price targets and ratings for companies in the homebuilding, technology, and biotechnology sectors. These adjustments reflect ongoing evaluations of company performance, market conditions, and future growth prospects. The updates were reported by Benzinga on April 13, 2026.

The firm also upgraded the stock from In-Line to Outperform. 12 on the previous Friday.

S. regions. Such rating upgrades can signal analysts' increased confidence in the company's ability to navigate housing market dynamics, including interest rates and demand trends. Investors often monitor these changes for insights into sector health.

Updates on Bilibili Inc Morgan Stanley adjusted its price target for Bilibili Inc ADR (NASDAQ:

BILI) upward from $25 to $31.

The firm upgraded the stock from Equal-Weight to Overweight. 76 on Friday. Bilibili is a Chinese online entertainment platform known for video sharing, live streaming, and anime content. S. exchanges, providing international investors access to the company.

This upgrade may indicate positive views on Bilibili's user growth and advertising revenue potential amid competition in the digital media space. These analyst actions occur against a backdrop of global economic factors affecting tech firms, such as regulatory environments in China and shifts in consumer spending.

Further details on other analysts' views are available through Benzinga's ratings page.

Biotechnology Sector Adjustment HC Wainwright & Co.

increased the price target for Oruka Therapeutics Inc (NASDAQ: ORKA) from $40 to $70. The firm maintained its Buy rating on the stock. 58 on Friday. Oruka Therapeutics is a biotechnology company developing treatments for dermatological conditions.

Maintaining a Buy rating while raising the target suggests sustained optimism about its pipeline and clinical progress. The stock's performance could influence investor interest in biotech innovations targeting skin disorders. Biotech firms like Oruka often face volatility due to clinical trial outcomes and regulatory approvals.

These updates provide a snapshot of analyst sentiment, which can guide investment decisions but should be considered alongside broader market data. Overall, these changes highlight varied analyst perspectives across sectors. For comprehensive analyst ratings, including upgrades and downgrades, refer to dedicated tracking resources.

The full details of additional forecasts, such as those for Netflix mentioned in related coverage, are available on Benzinga.